宫颈癌顺铂耐药研究进展

Research progress on cisplatin resistance in cervical cancer

顺铂(DDP)作为第一个被发现的金属抗癌药物,是目前最有潜力和应用最广泛的抗肿瘤药物。顺铂在宫颈癌的治疗中尤为重要,目前已被推荐为同步放化疗的首选药物。但随着广泛的使用,顺铂的耐药性逐渐显露出来,并成为限制临床疗效和部分患者肿瘤治疗进展的主要原因之一。顺铂的耐药机制复杂,发生环节较多,但具体耐药机制尚不明确,目前按照顺铂耐药发生的环节可分为:①顺铂在血液循环过程中产生耐药;②顺铂通过细胞膜的流入或流出产生耐药;③顺铂在胞质中产生耐药;④顺铂与DNA结合后产生耐药。本文综述了宫颈癌顺铂耐药可能发生的四个环节及克服耐药常用的手段,为提高顺铂对宫颈癌的疗效提供依据。

As the first metal anticancer drug discovered,cisplatin(DDP)is the most potential and widely used antineoplastic drug.Cisplatin is the first choice for concurrent chemoradiotherapy in cervical cancer.However,with the widespread use,cisplatin resistance was gradually revealed and became one of the main reasons for poor clinical efficacy and disease progression in some patients.The mechanism of cisplatin resistance is complex and involves many processes,but the specific mechanism of cisplatin resistance is still unclear now.In this article it is accepted that cisplatin resistance may be occurred at four different moments.During drug circulation through blood stream,during drug influx and efflux through cell membrane,during present in cytoplasm and finally after DNA binding.The four possible links of cisplatin resistance in cervical cancer and the common methods to overcome the drug resistance is reviewed in this review,so as to provide the basis for improving the curative effect of cisplatin on cervical cancer.